Value Investing Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Value Investing

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Madharry who wrote (38645)	7/30/2010 1:56:58 AM
From: Spekulatius	Read Replies (3) of 78673

I assume you mean Covidien (COV) . Efficiency was not the problem, their earnings were great, but topline was lacking. i think management is doing a decent job since they were spun of from Tyco. Back then, they were generating decent profits but sales growth was anemic and the product line was stale due to years of skimping on R&D. Over the years, they bumped up R&D, restructured the company and improved the balance sheet. Operating earnings are about 40% higher than after the spinoff, but the stock is lower than it was back then. I bought some around 32$ last year and peeled of shares at around 42$ and 50$. unfortunately I rode some remaining shares down to 37$. Now I am buying again. As for GFRE,the mixed shelf is bad news. 120M$ is quite a bit of capital for a 300M$ market cap company. it sounds like they are hellbent on expansion. that is not good for shareholders. Maybe I fish for some shares in the 7.XX$ range. This is a very zippy trading vehicle.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next